Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?

The development of effective therapies for colorectal cancer depends on the ability of preclinical models to faithfully recapitulate the molecular and biological behavior of human tumors. This study reports the characterization of colorectal GEMMs and their derivative cell lines carrying wild-type or oncogenic Kras with concomitant Apc and p53 loss.